CRISPR Therapeutics AG (CRSP) earnings date
Feb 16, 2027, after close estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 27% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-20
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 36 days, typically, give or take 4 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Mon, Nov 2, 2026 | after close | 33 | 8-K |
| Q2 FY2026 | Mon, Aug 3, 2026 | after close | 34 | 8-K |
| Q1 FY2026 | Mon, May 4, 2026 | after close | 34 | 8-K |
| Q4 FY2025 | Thu, Feb 12, 2026 | after close | 43 | 8-K |
| Q3 FY2025 | Mon, Nov 10, 2025 | before open | 41 | 8-K |
| Q2 FY2025 | Mon, Aug 4, 2025 | after close | 35 | 8-K |
| Q1 FY2025 | Tue, May 6, 2025 | after close | 36 | 8-K |
| Q4 FY2024 | Tue, Feb 11, 2025 | after close | 42 | 8-K |
What they guided beta
| Q3 FY2026 | "Phase 1b data in patients with sHTG will be presented in a late-breaking oral presentation at the American Heart Association (AHA) Scientific Sessions 2026 on November 9, 2026, at 8:00 a.m. CT." exhibit |
| Q3 FY2026 | "CRISPR Therapeutics has completed enrollment in the Phase 2 clinical trial of CTX611 (SRSD107), a long-acting siRNA therapeutic targeting Factor XI (FXI), in patients undergoing total knee arthroplasty (TKA), with an update expected in the second half of 2026." exhibit |
| Q3 FY2026 | "CRISPR Therapeutics has the option to nominate up to two additional siRNA targets, with an update expected in 2027." exhibit |
| Q3 FY2026 | "Phase 1 clinical data in patients with refractory SSc will be presented in a poster presentation at the American College of Rheumatology (ACR) Convergence 2026 on November 8 at 10:30 a.m. ET." exhibit |
| Q2 FY2026 | "We enter the second half of 2026 well positioned, with a number of important milestones ahead across our pipeline." Recent Highlights and Outlook Hemoglobinopathies and CASGEVY® (exagamglogene autotemcel) CASGEVY is a non-viral, ex vivo , CRISPR/Cas9 gene-edited cell therapy for eligible patients with SCD or TDT that has been shown to reduce or eliminate vaso-occlusive crises (VOCs) for patients with SCD and transfusion requirements for patients with TDT." exhibit |
| Q2 FY2026 | "CRISPR Therapeutics announced that a late-breaking abstract entitled " Durability of Effects of CTX310, a CRISPR-Cas9 Gene Editing Targeting ANGPTL3 " has been accepted for presentation at the European Society of Cardiology (ESC) Congress 2026 in Munich, Germany, on August 28 at 4:30 p.m. CET to discuss a clinical update of the ongoing Phase 1a trial." exhibit |
| Q2 FY2026 | "The Company also expects to provide a Phase 1b clinical update in the second half of 2026." exhibit |
| Q2 FY2026 | "An Lp(a) program update is anticipated in 2026. siRNA-based Programs CRISPR Therapeutics' small interfering RNA (siRNA)-based portfolio includes clinical-stage programs targeting cardiovascular and thromboembolic diseases, developed in collaboration with Sirius Therapeutics." exhibit |
| Q2 FY2026 | "The Company expects to provide an update in the second half of 2026." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/CRSP
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/CRSP
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/CRSP/"><img src="https://veritasdata.dev/embed/CRSP.svg" alt="CRSP earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/CRSP/)
Script
<script async src="https://veritasdata.dev/embed/CRSP.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/CRSP"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.